En
Fr
(
Fr
)
Contact Us
Home
About Us
Our Company
Our Values
Our Strategy
Meet the Management Team
Our Board Members
Product Pipeline
R&D Pipeline
Fezagepras
Selective GPR84 Antagonist
Selective OXER1 Antagonist
Plasminogen Deficiency
Scientific Posters
Investors & Media
Investor Resources
Press Releases
Financial Reports
Webcasts
SEC Filings
Stock Information
Corporate Governance
Investor Briefcase
Frequently Asked Questions
Careers
Career Opportunities
Resume Submission
Subscribe
Home
About Us
Our Company
Our Values
Our Strategy
Meet the Management Team
Our Board Members
Product Pipeline
R&D Pipeline
Fezagepras
Selective GPR84 Antagonist
Selective OXER1 Antagonist
Plasminogen Deficiency
Scientific Posters
Investors & Media
Investor Resources
Press Releases
Financial Reports
Webcasts
SEC Filings
Stock Information
Corporate Governance
Investor Briefcase
Frequently Asked Questions
Careers
Career Opportunities
Resume Submission
Subscribe
Product Pipeline
Therapeutics
Pre-clin
Phase 1
Phase 2
Phase 3
NDA/BLA
Phase
Ryplazim®
Congenital Deficiency (BLA filed)
Learn More
Fezagepras (PBI-4050)
Additional Multiple Ascending Dose (MAD) Study
Selective GPR84 Antagonist
Fibrosis
Learn More
Selective OXER1 Antagonist
Respiratory/GI
Learn More
